Search Results for “EC” – media

KeyMed’s second breakthrough

While some pharmaceutical companies are trapped in the red sea of internal volume and cannot extricate themselves, KeyMedhas completed the second breakthrough of external volume. On November 17, KeyMedBio issued an announcement to license its autoimmune bispecific antibody pipeline CM336 to a foreign company. The transaction party is a startup company registered in the UK called Platina Medicines Ltd (PML). The form of this transaction is a NewCo form with cash and equity in parallel. It is worth mentioning that this is the second NewCo overseas expansion of KeyMedBio in 2024 after the US$185 million transaction with Belenos Biosciences in July. When KeyMedachieves a second breakthrough of external volume, what kind of surprise will it bring to the market? The BD of the second breakthrough targets the CM336 pipeline, targeting the BCMA×CD3 dual targets, which is the same target as the bispecific antibody of the BD of Epimed Bio two ...
- Source: drugdu
- 30
- November 23, 2024
Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan

November 21, 2024 07:30 Author: Du Sumin Source: Time Weekly 1 In just one week, two business development (BD) transactions with a total transaction amount exceeding 20 billion yuan have made innovative pharmaceutical company Lixin Pharmaceutical the focus of attention in the industry. On November 20th, China Biopharmaceutical (01177.HK, hereinafter referred to as “Zhongsheng Pharmaceutical”) announced that it had signed an equity investment and strategic cooperation agreement with Lixin Pharmaceutical. Accordingly, with an investment of 142 million yuan, Sinopharm will acquire 4.91% of the equity of Lixin Pharmaceutical. At the same time, it will reach strategic cooperation in Chinese Mainland on the LM-108 monoclonal antibody targeting CCR8 independently developed by Lixin Pharmaceutical, and has the right to choose multiple double antibody or ADC innovative drugs in the research pipeline of Lixin Pharmaceutical for cooperation. The specific terms will be otherwise agreed. This is the second BD transaction conducted by Lixin ...
- Source: drugdu
- 43
- November 22, 2024
Junshi Biotechnology introduces two cancer dual target fusion protein drugs

On the evening of November 19th, Junshi Biotechnology announced that it had signed a license agreement with the licensor. The licensor granted Junshi Biological the exclusive license right and sub license right to develop, manufacture, use, import, export, sell and commercialize the two double target fusion proteins in the Greater China region (including the Chinese Mainland, Hong Kong, Macao and Taiwan regions). At the same time, Junshi Biological and the licensor enjoy all the rights and interests to develop, manufacture, use, import, export, sell and commercialize one of the licensed products in the world in accordance with the equity ratio of 50%: 50%. After the signing of the license agreement, Junshi Biotechnology will make a down payment of 1.5 million US dollars (approximately 10.86 million RMB) to the licensor. Junshi Biotechnology will pay a milestone payment of no more than RMB 740 million to the licensor based on the progress ...
- Source: drugdu
- 38
- November 22, 2024
This “excellent hospital director” took the initiative to explain the problem

Eight months after leaving office, Liu Qunyou, former Party Secretary of the First People’s Hospital of Xiangtan City, Hunan Province, was investigated. According to the Xiangtan Municipal Commission for Discipline Inspection and Supervision on November 12, Liu Qunyou was suspected of serious violations of discipline and law, and took the initiative to explain the problem to the organization. He is currently undergoing disciplinary review and supervision investigation. Public information shows that Liu Qunyou is 60 years old, from Xinning, Hunan Province, with a bachelor’s degree, deputy chief physician, master’s tutor, graduated from Tongji Medical College of Huazhong University of Science and Technology, and is an in-service graduate student of Xiangya Medical College of Central South University. After graduating from university in 1986, he was assigned to Xiangtan First People’s Hospital and worked in the medical field for 38 years. In March this year, 60-year-old Liu Qunyou resigned from the post ...
- Source: drugdu
- 33
- November 22, 2024
The director of the National Medical Insurance Bureau expressed his position to promote direct settlement of medical insurance

On November 14, 2024, Zhang Ke, secretary of the Party Leadership Group and director of the National Medical Insurance Bureau, went to Xicheng District, Beijing to investigate medical insurance work. He visited the Xicheng District Medical Insurance Bureau and the Medical Insurance Affairs Management Center to learn more about the total budget management of medical insurance funds, the settlement process with designated medical institutions, and the allocation of funds. Zhang Ke said that the medical insurance department of Beijing should take the lead in trialing and innovating the settlement methods of medical insurance funds, and explore the construction of a scientific medical insurance settlement system based on direct settlement, instant settlement, and synchronous settlement. It is necessary to actively promote direct settlement and instant settlement between medical insurance and hospitals, pharmaceutical companies, and equipment and consumables manufacturers. For a long time, the long collection cycle has imposed a heavy financial ...
- Source: drugdu
- 31
- November 22, 2024
【EXPERT Q&A】How to check the drug registration standards? Where do you find it?

Drugdu.com expert’s response: The inquiry of drug registration standards typically involves multiple levels and channels. Here are some suggested methods and avenues for inquiry: Ⅰ. Methods of Inquiry Official Website Inquiry: (1) CDE (National Medical Products Administration’s Center for Drug Evaluation) Website: CDE is responsible for the evaluation of drug registration applications, and its website usually publishes information related to drug registration. Through sections such as “Information Disclosure” or “Application Directory Browsing” on the CDE website, you can inquire about the overall acceptance status of drug registration applications and the progress of evaluation and approval. Additionally, CDE provides specific inquiry services for the acceptance, evaluation, and approval progress of drug registration applications, and applicants can inquire through the “Applicant’s Window” section. (2) National Medical Products Administration Website: The National Medical Products Administration is the authoritative agency for drug registration approval, and its website also publishes information and policies related to ...
- Source: drugdu
- 34
- November 22, 2024
Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding?

Jingtai Technology, which has the halo of being the “first AI pharmaceutical stock” in China, has attracted considerable attention in the secondary market. In the past few months, it has always sparked discussions within the industry due to occasional breakthroughs. According to Wind, on November 19th, Jingtai Technology’s lowest intraday price was HKD 3.51 per share, hitting a new low since its listing. The closing price for the day was HKD 4.00 per share, a drop of 12.66%. Compared to its issue price of HKD 5.28 per share, it has dropped 24.24%. In fact, since September this year, the stock price of Jingtai Technology has shown an overall fluctuating downward trend. According to the official website of Jingtai Technology, it is an innovative research and development platform company driven by artificial intelligence (AI) and robots. Based on technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale ...
- Source: drugdu
- 43
- November 21, 2024
EMA recommends approval of Lencanermab

After four months of deliberation, the European Medicines Agency (EMA) has “changed its mind” on Lencanermab. On November 14, the EMA Committee for Medicinal Products for Human Use (CHMP) announced that after re-examining Lencanermab, it recommended approval of Lencanermab for the treatment of mild cognitive impairment or mild dementia caused by Alzheimer’s disease, suitable for apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. According to regulations, the European Commission is expected to make a final ruling on the marketing authorization application for Lencanermab within the next 67 days. Of course, the European Commission is not in a good position to raise objections, so it is equivalent to approval. Although we had expected this result four months ago, it can be imagined that there were a lot of discussions in the middle. Foreign media commented that “EMA’s attitude towards Lencanermab has reversed 180 degrees.” This time, after Eisai/Biogen submitted the subgroup ...
- Source: drugdu
- 40
- November 21, 2024
AstraZeneca’s new dual anti-cancer drug approved for clinical trials in China

On November 15, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that AstraZeneca’s Class 1 new drug AZD0486 was approved for two clinical trials with implicit approval, which are intended to be used for the treatment of previously untreated follicular lymphoma in adults; and relapsed and refractory follicular lymphoma in adults who have received at least 2 lines of systemic treatment or more. Public information shows that AZD0486 is a CD19/CD3-targeted bispecific T cell adaptor protein under development by AstraZeneca, which is a next-generation T cell adaptor. This is the first time that a drug has been approved for clinical trials in China for the indication of follicular lymphoma (FL). In a clinical study recently published by AstraZeneca, the product showed an overall response rate (ORR) of up to 96% when used to treat patients with relapsed/refractory FL (R/R FL). ...
- Source: drugdu
- 38
- November 21, 2024
Barco showcases new products at CCR2024, adding momentum to precision medicine

The 31st Radiology Academic Conference of the Chinese Medical Association (CCR2024) was held at the Shanghai World Expo Center from November 14th to 17th. Barco showcased its new Coronis OneLook 32MP multimodal diagnostic imaging display, integrated reading center, and multiple radiology displays at the booth, bringing cutting-edge technology and outstanding products to the Chinese precision medicine market with updated and more comprehensive solutions. New product One Look 32MP unveiled, showcasing higher standards in the medical display field The display is a bridge connecting radiologists and medical imaging, and its performance directly affects the accuracy of doctors’ capture, interpretation, and diagnosis of image details. At this conference, Barco unveiled its new Coronis OneLook 32MP multimodal fusion display, bringing more refined solutions to the Chinese medical market. The Coronis OneLook 32MP multimodal fusion display is Barco’s industry-leading medical display solution, featuring a 32MP ultra high definition resolution and a 33 inch large ...
- Source: drugdu
- 53
- November 20, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.